Two diverse carriers are better than one: A case study in α‐particle therapy for prostate specific membrane antigen‐expressing prostate cancers-Reference-Cited by-同舟云学术

Two diverse carriers are better than one: A case study in α‐particle therapy for prostate specific membrane antigen‐expressing prostate cancers

Published:2021-11-17 Issue: Volume: Page:
ISSN:2380-6761
Container-title:Bioengineering & Translational Medicine
language:en
Short-container-title:Bioeng Transl Med

Author:

Salerno Dominick¹,Howe Alaina¹,Bhatavdekar Omkar¹,Josefsson Anders²^ORCID,Pacheco‐Torres Jesus²,Bhujwalla Zaver M.²,Gabrielson Kathleen L.³,Sofou Stavroula¹⁴^ORCID

Affiliation:

1. Chemical and Biomolecular Engineering (ChemBE) Institute for NanoBioTechnology (INBT) Johns Hopkins University Baltimore Maryland USA

2. Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University Baltimore Maryland USA

3. Molecular and Comparative Pathobiology Johns Hopkins University Baltimore Maryland USA

4. Sidney Kimmel Comprehensive Cancer Center, Cancer Invasion & Metastasis Program, Department of Oncology Johns Hopkins University Baltimore Maryland USA

Funder

National Institutes of Health

Patrick C. Walsh Prostate Cancer Research Fund

Publisher

Wiley

Subject

Pharmaceutical Science,Biomedical Engineering,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/btm2.10266

Reference36 articles.

1. Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group;Miyahira Andrea K;Prostate,2018

2. Targeted α‐therapy of metastatic castration‐resistant prostate cancer with 225Ac‐PSMA‐617: dosimetry estimate and empiric dose finding;Kratochwil C;J Nucl Med,2017